All In Biotech

Drug Trial Radar · NCT05519085

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing Mezigdomide (CC-92480), Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM): SUCCESSOR-1

Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 810 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

810

Planned (sponsor's estimate)

Start

Sep 20, 2022

Primary completion

Jan 10, 2027

Study completion Nov 30, 2033

Sponsor

Lead sponsor
CelgeneBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Aug 29, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the efficacy and safety of mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory multiple myeloma (RRMM) who received between 1 to 3 prior lines of therapy and who have had prior lenalidomide exposure.

Conditions

  • Relapsed or Refractory Multiple Myeloma

Interventions

  • mezigdomideDrug

    Specified dose on specified days

  • PomalidomideDrug

    Specified dose on specified days

  • BortezomibDrug

    Specified dose on specified days

  • DexamethasoneDrug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free Survival (PFS)Time frame: From date of randomization to date of disease progression or death due to any cause (Up to approximately 5 years)

Locations

266 sites in 29 countries. Site status is shown where the registry gives one.

  • Local Institution - 0366

    Los Alamitos, California · Active not recruiting

  • Local Institution - 0272

    San Diego, California · Completed

  • Local Institution - 0273

    West Hollywood, California · Completed

  • Local Institution - 0381

    Aurora, Colorado · Not yet recruiting

  • Local Institution - 0380

    Farmington, Connecticut · Completed

  • Local Institution - 0208

    New Haven, Connecticut · Withdrawn

  • Local Institution - 0303

    Coral Springs, Florida · Active not recruiting

  • Local Institution - 0403

    Fort Myers, Florida · Completed

  • Local Institution - 0401

    Orange City, Florida · Active not recruiting

  • Local Institution - 0402

    West Palm Beach, Florida · Active not recruiting

  • Local Institution - 0211

    Athens, Georgia · Active not recruiting

  • Local Institution - 0048

    Marietta, Georgia · Withdrawn

  • Local Institution - 0330

    Garden City, Kansas · Completed

  • Local Institution - 0080

    Westwood, Kansas · Active not recruiting

  • Local Institution - 0358

    Baton Rouge, Louisiana · Active not recruiting

  • Local Institution - 0255

    New Orleans, Louisiana · Active not recruiting

  • Local Institution - 0385

    Shreveport, Louisiana · Not yet recruiting

  • Local Institution - 0357

    Baltimore, Maryland · Completed

  • Local Institution - 0246

    Boston, Massachusetts · Active not recruiting

  • Local Institution - 0271

    Ann Arbor, Michigan · Active not recruiting

  • Local Institution - 0364

    Detroit, Michigan · Completed

  • Local Institution - 0410

    Minneapolis, Minnesota · Active not recruiting

  • Local Institution - 0088

    Hattiesburg, Mississippi · Active not recruiting

  • Local Institution - 0242

    Jackson, Mississippi · Withdrawn

  • Local Institution - 0288

    East Brunswick, New Jersey · Active not recruiting

  • Local Institution - 0363

    Ridgewood, New Jersey · Not yet recruiting

  • Local Institution - 0302

    Albuquerque, New Mexico · Active not recruiting

  • Local Institution - 0245

    Buffalo, New York · Withdrawn

  • Local Institution - 0257

    Lake Success, New York · Active not recruiting

  • Local Institution - 0373

    New Hyde Park, New York · Completed

  • Local Institution - 0371

    New York, New York · Completed

  • Local Institution - 0108

    Rochester, New York · Active not recruiting

  • Local Institution - 0374

    Shirley, New York · Completed

  • Local Institution - 0372

    The Bronx, New York · Completed

  • Local Institution - 0274

    Williamsville, New York · Withdrawn

  • Local Institution - 0260

    Durham, North Carolina · Active not recruiting

  • Local Institution - 0400

    Cincinnati, Ohio · Completed

  • Local Institution - 0377

    Cleveland, Ohio · Active not recruiting

  • Local Institution - 0076

    Cleveland, Ohio · Active not recruiting

  • Local Institution - 0376

    Mayfield Heights, Ohio · Completed

Showing 40 of 266 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.